Home » Therapeutic Areas » Neuro-Oncology

Neuro-Oncology Therapeutic Area

Neuro-Oncology Imaging CRO

As a specialist neuro-oncology imaging CRO, we deliver standardized assessments using RANO and RANO 2.0 and apply advanced MRI techniques to support the evaluation of true progression and treatment-related changes, including pseudoprogression.

0

Years of Imaging Expertise!

0

Clinical Trials Supported

Global

Site & Investigator Network

Compliance & Certificates

SOC 2 TYPE II

HHS-Seal

GDPR

FDA 21 CFR Part 11

ISO 13485

Imaging endpoints in neuro-oncology trials

Standardized RANO 2.0 Assessment for Glioma and GBM Trials

In glioblastoma and glioma trials, accurate image interpretation is critical to the assessment of treatment response. On conventional MRI, treatment-related changes can overlap with tumor progression, creating challenges for the consistent assessment of disease status across timepoints and readers.

RANO 2.0 provides an updated framework for response assessment, but its consistent application requires expertise in neuro-oncology imaging, standardized acquisition and experienced subspecialist readers.

IAG supports neuro-oncology studies from imaging strategy and protocol development through site qualification and centralized image review. Led by specialist neuroradiology expertise, we deliver standardized, auditable assessments through DYNAMIKA™ across the full imaging workflow.

Learn more

What our neuro-oncology imaging team does

Neuro-Oncology Imaging Capabilities

Imaging charter and sequence harmonization, site qualification, subspecialist reader qualification and adjudication — with advanced MRI and retrospective RANO 2.0 re-evaluation where your dataset supports it.

Advanced imaging for treatment-related changes

DWI, perfusion and DCE-MRI, with molecular imaging where appropriate, can support the assessment of tumor progression and treatment-related changes, including pseudoprogression.

RANO 2.0 retrospective analysis

Re-evaluation of existing imaging datasets using updated response assessment criteria, where image acquisition and available data support retrospective application.

Study Phases

How Image Analysis Group (IAG) Supports Neuro-Oncology Trials

From RANO 2.0 re-reads of legacy data to registrational central review, we match the imaging service to your program stage.<br />

Collect & Hold

Prospective or retrospective collection and secure archival — including re-evaluation of existing datasets against RANO 2.0 where acquisition supports it.

Collect & Hold

Early Phase Trials

Advanced MRI protocol design and exploratory analysis to characterize treatment-related change before your pivotal endpoint is fixed.

Early Phase Trials

Late Phase Trials

Blinded central review by subspecialist neuroradiologists applying RANO and RANO 2.0 with adjudication and full auditability.

Late Phase Trials

RWE & AI Studies

Submission-ready datasets, TFLs and reader variability analyses aligned to regulatory expectations for CNS tumor endpoints.

RWE & AI Studies

The experts behind your reads

Neuro-Oncology Imaging Experts

Neuroradiologists and quantitative imaging scientists with deep glioblastoma and glioma experience, leading read design, reader qualification and advanced MRI methodology.

Scientific Advisor — Neuro-Oncology, Brain Tumor Immunotherapy

Scientific Advisor — Neuro-Oncology Clinical Research, Brain Tumor Imaging

Criteria, measures and modalities we work in

RANO, RANO 2.0 and Quantitative Neuro-Oncology Measures

RANO, RANO 2.0 and RAPNO, supported by volumetric assessment, diffusion and perfusion metrics and advanced MRI measures that help separate treatment-related change from true progression.

Criterion

Applies to

RANO 2.0

Response Assessment in Neuro-Oncology

RAPNO

Response Assessment in Pediatric Neuro-Oncology

Indications we cover

Neuro-Oncology Indications We Support

Primary brain tumors, brain metastases, CNS lymphoma and pediatric brain tumors, with read methodology matched to enhancing and non-enhancing disease assessment.

Glioblastoma

In GBM, post-treatment enhancement can mimic tumour growth and cost a trial its endpoint. We apply RANO and RANO 2.0 through subspecialist neuroradiology review, standardize MRI sequence selection across sites, and add diffusion and perfusion measures to support assessment of pseudoprogression.

Diffuse Gliomas

Lower-grade gliomas change slowly, so sensitivity to small structural change matters more than speed. We standardize longitudinal MRI acquisition and support volumetric assessment of non-enhancing disease under RANO 2.0.

Brain Metastases

CNS response often needs to be reported separately from systemic disease. We define lesion selection and slice thickness requirements for small metastases and manage paired CNS and systemic reads within one blinded workflow.

Primary CNS Lymphoma

PCNSL responds rapidly and is steroid-sensitive, making acquisition timing critical. We fix imaging windows and contrast protocols in the charter and use neuroradiologists experienced in CNS lymphoma assessment.

Meningioma

Slow-growing extra-axial tumours require reproducible measurement over long follow-up. We standardize MRI acquisition and support volumetric assessment to detect change reliably across years of imaging.

Paediatric Brain Tumours

Paediatric CNS trials need age-appropriate protocols and criteria built for children. We apply RAPNO, design acquisition that manages motion and sedation requirements, and use paediatric neuroradiology readers.

Spinal Cord Tumors

Cord lesions are small and prone to motion and susceptibility artefact. We specify dedicated spinal sequences and positioning in the charter and centralize review to keep measurement consistent across timepoints.

Why Sponsors Choose IAG

One Platform Behind Every Neuro-Oncology Read

DYNAMIKA™ supports standardized RANO and RANO 2.0 assessment of enhancing and non-enhancing disease, with subspecialist reader management, adjudication workflows and a complete audit trail.

Centralized, secure data collection

DYNAMIKA™ unifies global imaging into a single cloud-native environment — GxP-validated, SOC 2 Type II and 21 CFR Part 11 compliant.

Real-time visibility and oversight

24/7 access to imaging status for every stakeholder, with site and reader performance tracked as the study runs.

Quality control and automated anonymization

Automated checks on receipt produce de-identified, QC-passed datasets before any read begins.

Consistent, standardized reads

Protocol-driven central reviews deliver standardized and reproducible assessment of enhancing and non-enhancing disease using the response criteria and measurement methodology appropriate to the study, including RANO and RANO 2.0 where applicable.

Neuro-Oncology

Reader management and audit trails

Subspecialist neuroradiologists are qualified against the response criteria and assessment methodology relevant to the study. Reader assignment, blinding and adjudication workflows including 2+1 models where required are managed in-platform, with every action fully auditable.